Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple dose-escalation study of INCB054707 in healthy Japanese participants
jRCT2071210079Phase 1Completed
- Sponsor
- Incyte
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of povorcitinib in Inflammatory Disorders (4 arms), sponsored by Incyte. Primary endpoints: Number of participants with treatment-emergent adverse events (TEAEs), Cmax of INCB054707 and 5 more. Started Oct 2021; status: completed.
02
Drugs
povorcitinib
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on jRCT2071210079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210079.